Evidence map›Paper›PMID 29715200›Full record

ArticleThe Journal of clinical investigation2018

TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis.

Ramesh Singh, Dileep Karri, Hong Shen, Jiangyong Shao, Subhamoy Dasgupta, Shixia Huang, Dean P Edwards, Michael M Ittmann, Bert W O'Malley, Ping Yi

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 80 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. OrthogonalApplied and environmental microbiology · 2025
    Article
  9. Article
  10. Tumor Innervation: From Bystander to Emerging Therapeutic Target for Cancer.International journal of molecular sciences · 2025
    Review
  11. Review
  12. Targeting nerve growth factor: an Achilles' heel for tumors?Journal for immunotherapy of cancer · 2025
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Ramesh SinghDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.
Dileep KarriDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.
Hong ShenDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.
Jiangyong ShaoDiana Helis Henry Medical Research Foundation, New Orleans, Louisiana, USA.
Subhamoy DasguptaDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.
Shixia HuangDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.
Dean P EdwardsDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.
Michael M IttmannDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA.
Bert W O'MalleyDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.
Ping YiDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.
Baylor College of Medicine · USDan L Duncan Comprehensive Cancer CenterOrthopaedic Research Foundation · US

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9M
INVESTIGATING THE ROLE OF THE TRANSCRIPTIONAL COREGULATOR SRC-2 IN CASTRATION RESISTANT PROSTATE CANCERK22CA207578 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI DASGUPTA, SUBHAMOY · 2017 to 2019
$620k
NCI NIH HHS K22 CA207578NCI NIH HHS P30 CA125123
6 · The paper itself

Abstract

Receptor tyrosine kinases (RTKs) are important drivers of cancers. In addition to genomic alterations, aberrant activation of WT RTKs plays an important role in driving cancer progression. However, the mechanisms underlying how RTKs drive prostate cancer remain incompletely characterized. Here we show that non-proteolytic ubiquitination of RTK regulates its kinase activity and contributes to RTK-mediated prostate cancer metastasis. TRAF4, an E3 ubiquitin ligase, is highly expressed in metastatic prostate cancer. We demonstrated here that it is a key player in regulating RTK-mediated prostate cancer metastasis. We further identified TrkA, a neurotrophin RTK, as a TRAF4-targeted ubiquitination substrate that promotes cancer cell invasion and found that inhibition of TrkA activity abolished TRAF4-dependent cell invasion. TRAF4 promoted K27- and K29-linked ubiquitination at the TrkA kinase domain and increased its kinase activity. Mutation of TRAF4-targeted ubiquitination sites abolished TrkA tyrosine autophosphorylation and its interaction with downstream proteins. TRAF4 knockdown also suppressed nerve growth factor (NGF) stimulated TrkA downstream p38 MAPK activation and invasion-associated gene expression. Furthermore, elevated TRAF4 levels significantly correlated with increased NGF-stimulated invasion-associated gene expression in prostate cancer patients, indicating that this signaling axis is significantly activated during oncogenesis. Our results revealed a posttranslational modification mechanism contributing to aberrant non-mutated RTK activation in cancer cells.

Indexed as

AnimalsCell Line, TumorCell MovementGene Expression Regulation, NeoplasticGene Knockdown TechniquesHeterograftsHumansLung NeoplasmsMaleMiceMice, Inbred NODMice, SCIDNeoplasm InvasivenessNeoplasm TransplantationPC-3 CellsProstatic NeoplasmsNTRK1 protein, humanReceptor, trkARNA, MessengerRNA, Small InterferingTNF Receptor-Associated Factor 4TRAF4 protein, humanCell BiologyGeneticsProstate cancerProtein kinasesUbiquitin-proteosome system

Identifiers

PMID29715200
PMCPMC6026011
OpenAlexW2802842470

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.